Fig. 1 · Structure

Documents & Downloads

Dihydroartemisinin

Cat. No. A10310 CAS 71939-50-9
Dihydroartemisinin is the active metabolite of all artemisinin compounds (artemisinin, artesunate, artemether, etc.) and is also available as a drug in itself. It is a semi-synthetic derivative of artemisinin and is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs.

In Stock

Publications for Dihydroartemisinin

1 publication citing this product

  1. Xinyu Zhou, .et al. , Cancers (Basel), 2020, Sep; 12(9): 2514 PMID: 32899699

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In HCT116 colorectal cancer cells, P53 depletion attenuated DHA-associated DR5 upregulation, while residual DR5 induction remained. This supports a contributory role for P53 in this cellular response. [1]

In mouse embryonic fibroblasts, DHA-associated ferritin heavy-chain reduction persisted after Atg5 loss and was opposed by bafilomycin A1. These results support lysosome-dependent ferritin regulation that does not require Atg5 in this model. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
RelA  
Plasmodium  
Autophagy  

Dihydroartemisinin Research Summary

This section summarizes 3 in vitro studies and 2 in vivo studies of Dihydroartemisinin from 3 published references. In vitro models include HCT116 and DLD-1 human colorectal cancer cells.

Dihydroartemisinin In Vitro Studies

DHA pretreatment followed by the DR5-specific TRAIL variant DHER increased annexin V/PI-defined apoptosis compared with either agent alone in HCT116 and DLD-1 colorectal cancer cells. The combination used 10 μM DHA and 25 ng/mL DHER; this result does not define a DHA-alone IC50. [1]

DHA augments DHER-associated apoptosis in colorectal cancer cells

Cell-based study · HCT116 and DLD-1 human colorectal cancer cells [1]

The DHA plus DR5-specific TRAIL variant DHER combination increased annexin V/PI-defined apoptosis relative to either single treatment. Unstimulated and both single-treatment controls were included. This is combination evidence; the readouts do not establish DHA-alone potency.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Annexin V/PI-defined apoptosisqualitative comparison Higher with DHA + DHER than with either agent alone in both cell lines[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM DHA; 25 ng/mL DHER
Exposure duration
DHA pretreatment for 30 min, followed by DHER for 16 h
Method
Cell treatment
Vehicle
DHA dissolved in DMSO; final DMSO <1% in all experiments
Co-treatment
DR5-specific TRAIL variant DHER
Reported limits
Exact matched final DMSO concentration and independent replicate count for annexin V panels are not specified in the read caption/methods.
Methods and source locations

Compound reported in the paper: Dihydroartemisinin; Compound label in the paper: DHA

Compound-level findings in the reported models. No validation of current A10310 lots or equivalence of suppliers; no clinical efficacy inference.

Results 2.1; Figure 3C–E; Methods 4.1 and 4.3

Annexin V/PI-defined apoptosis: Annexin V-FITC/PI staining with flow cytometry; 10,000 events recorded per analysis — Figure 3C–E; Results 2.1; Methods 4.3

P53 depletion attenuates DHA-associated DR5 upregulation

Cell-based study · HCT116 colorectal cancer cells transfected with P53-targeting or control esiRNA [1]

P53-targeting esiRNA reduced P53 protein and attenuated the increase in DR5 after DHA, compared with control esiRNA. DR5 still increased in P53-depleted cells, supporting a contributory rather than exclusive role for P53.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
P53 knockdown verificationqualitative comparison P53 protein was lower with P53-targeting esiRNA than with control esiRNA[1]
DHA-associated DR5 protein response after P53 depletionqualitative comparison Attenuated but not abolished after P53 depletion[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM DHA
Exposure duration
48 h transfection followed by 24 h DHA exposure
Method
Cell treatment
Vehicle
DHA dissolved in DMSO; final DMSO <1%
Co-treatment
P53-targeting esiRNA versus control esiRNA; no DHER needed for the selected DR5 immunoblot comparison
Reported limits
Anomeric composition and lot unreported; uncropped supplementary Figure S3 not acquired. The precise independent n for panels C/E is not explicit in the caption; Methods 4.8 states the interfering assay was performed in triplicate.
Methods and source locations

Compound reported in the paper: Dihydroartemisinin; Compound label in the paper: DHA

Compound-level findings in the reported models. No validation of current A10310 lots or equivalence of suppliers; no clinical efficacy inference.

Results 2.5; Figure 7C and 7E; Methods 4.1, 4.5 and 4.8

P53 knockdown verification: Western blot with vinculin loading control — Figure 7C; Methods 4.8

DHA-associated DR5 protein response after P53 depletion: DR5 immunoblot and vinculin-normalized densitometry — Figure 7E; Results 2.5; Methods 4.5 and 4.8

Lysosome-sensitive ferritin reduction despite Atg5 loss

Cell-based study · Atg5-knockout mouse embryonic fibroblasts and Atg5-reconstituted counterparts [2]

DHA reduced ferritin heavy-chain (FTH1) protein in both Atg5-knockout and reconstituted MEFs; bafilomycin A1 opposed the reduction. This supports lysosome-dependent ferritin regulation that does not require Atg5 in this system.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ferritin heavy-chain protein in Atg5-deficient and reconstituted MEFsqualitative comparison DHA-associated FTH1 reduction was opposed by bafilomycin A1 in both genetic backgrounds[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM DHA (DAT); 20 nM bafilomycin A1 where indicated; 1 μM erastin comparator
Exposure duration
6 h for the Figure 4C immunoblot
Method
Cell treatment
Vehicle
Cell-treatment solvent not specified in the selected read sections
Co-treatment
Factorial DHA/erastin/bafilomycin A1 controls in Atg5-knockout and reconstituted cells
Reported limits
No exact densitometry or solvent percentage reported in the selected figure/caption; general statistics states SD, n=3 unless otherwise indicated, without identifying replicate type.
Methods and source locations

Compound reported in the paper: Dihydroartemisinin; Compound label in the paper: DAT

Compound-level findings in the reported models. No validation of current A10310 lots or equivalence of suppliers; no clinical efficacy inference.

Figure 4C and caption; Results: Lysosomal activity is required for DAT-sensitized ferroptosis; Antibodies and reagents

Ferritin heavy-chain protein in Atg5-deficient and reconstituted MEFs: FTH1 immunoblot with actin loading control; NCOA4 also shown — Figure 4C; associated Results paragraph

Dihydroartemisinin In Vivo Studies

In H292 xenografts with inducible GPX4 loss, daily intraperitoneal DHA at 5 mg/kg augmented tumor growth suppression relative to either intervention alone. Liproxstatin-1 partially reversed the effect, supporting a ferroptosis contribution in this engineered mouse model. [2]

In a separate CT26 mouse xenograft study, DHA at 50 mg/kg on Days 7, 9 and 11 did not significantly lower final tumor weight versus control. Adding DHA to three 6-Gy radiotherapy fractions did not significantly improve tumor weight versus radiotherapy alone. These negative findings apply to the tested regimen. [3]

DHA augments GPX4-loss-associated growth suppression in H292 xenografts

Animal study · Human H292 tumors carrying doxycycline-inducible GPX4 knockout in 6–8-week-old female athymic nude mice [2]

DHA plus doxycycline-induced GPX4 loss retarded tumor growth more than either intervention alone; liproxstatin-1 partially restored growth. The combination also lowered Ki67 staining. The result supports sensitization in this engineered model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Xenograft tumor growthqualitative comparison Combination suppressed growth more than either single intervention; liproxstatin-1 partially restored growth[2]
Tumor Ki67 and GPX4 stainingqualitative comparison Lower Ki67 with DHA plus induced GPX4 loss; GPX4 staining decreased in doxycycline-treated tumors[2]

Conditions shared by the study groups

Route
Intraperitoneal injections; diet for doxycycline
Frequency
Daily injections
Treatment course
Two weeks
Vehicle
Vehicle identity discrepant: saline in Methods, PBS in caption
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle and normal diet
Vehicle only
Vehicle/normal diet; DHA-alone and doxycycline-alone groups; rescue comparisonComparator[2]
DHA and normal diet
DHA 5 mg/kg
Vehicle/normal diet; DHA-alone and doxycycline-alone groups; rescue comparisonModest growth retardation relative to vehicle[2]
Induced GPX4 loss
Vehicle only
Vehicle/normal diet; DHA-alone and doxycycline-alone groups; rescue comparisonModest growth retardation relative to vehicle[2]
DHA plus induced GPX4 loss
DHA 5 mg/kg
Vehicle/normal diet; DHA-alone and doxycycline-alone groups; rescue comparisonGreater tumor growth suppression than either intervention alone[2]
Liproxstatin-1 rescue
DHA 5 mg/kg + liproxstatin-1 10 mg/kg
Vehicle/normal diet; DHA-alone and doxycycline-alone groups; rescue comparisonPartial restoration of tumor growth[2]
Vehicle and normal diet
Model: H292 inducible-GPX4-knockout xenografts; Normal diet
Reported limits: Sample size and doxycycline diet content not specified in read text/caption.
DHA and normal diet
Model: H292 inducible-GPX4-knockout xenografts; Normal diet
Reported limits: Sample size and doxycycline diet content not specified in read text/caption.
Induced GPX4 loss
Model: H292 inducible-GPX4-knockout xenografts; Doxycycline diet
Reported limits: Sample size and doxycycline diet content not specified in read text/caption.
DHA plus induced GPX4 loss
Model: H292 inducible-GPX4-knockout xenografts; Doxycycline diet
Reported limits: Sample size and doxycycline diet content not specified in read text/caption.
Liproxstatin-1 rescue
Model: H292 inducible-GPX4-knockout xenografts; Doxycycline diet
Reported limits: Sample size and doxycycline diet content not specified in read text/caption.
Methods and source locations

Compound reported in the paper: Dihydroartemisinin; Compound label in the paper: DAT

Compound-level findings in the reported models. No validation of current A10310 lots or equivalence of suppliers; no clinical efficacy inference.

Figure 6E–G; Results: DAT sensitizes cancer cells to ferroptosis – therapeutic potential; Methods: In vivo xenograft studies

Xenograft tumor growth: Daily caliper tumor-volume measurement; error bars standard error; no exact effect size extracted — Figure 6E–F and associated Results; In vivo xenograft studies

Tumor Ki67 and GPX4 staining: Tumor immunohistochemistry; qualitative comparison — Figure 6G and associated Results

Vehicle and normal diet · In vivo xenograft studies; Figure 6E–G

DHA and normal diet · In vivo xenograft studies; Figure 6E–G

Induced GPX4 loss · In vivo xenograft studies; Figure 6E–G

DHA plus induced GPX4 loss · In vivo xenograft studies; Figure 6E–G

Liproxstatin-1 rescue · In vivo xenograft studies; Figure 6E–G

No detectable additional benefit from DHA with hypofractionated radiotherapy

Animal study · CT26 colorectal tumor xenografts in female BALB/c nude mice, 6–8 weeks old; randomized, n=6 per group [3]

DHA alone did not significantly reduce final tumor weight relative to PBS control. RT and DHA+RT reduced tumor weight relative to control, but adding DHA did not significantly improve tumor weight over RT alone under this regimen. Non-significance does not demonstrate equivalence or exclude benefit under other conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Final tumor weight between treatment groupsreported significance comparisons Control versus DHA: p > 0.05; RT versus DHA+RT: p > 0.05; control versus RT and control versus DHA+RT: p < 0.05[3]

Conditions shared by the study groups

Vehicle
PBS control; DHA formulation unspecified
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PBS control
PBS
PBS controlComparator[3]
DHA alone
50 mg/kg
PBS controlNo significant final tumor-weight reduction versus PBS[3]
RT alone
6 Gy per fraction
PBS and DHA+RT groupsLower final tumor weight than control[3]
DHA plus RT
DHA 50 mg/kg + RT 6 Gy per fraction
RT aloneNo significant additional final tumor-weight reduction versus RT alone[3]
PBS control
Model: CT26 xenografts; female BALB/c nude mice; n=6/group
Route: Abdominal injection
Frequency: Comparator schedule; control injection frequency not separately explicit in prose
Treatment course: Day 15 tumor collection
Reported limits: No exact mean/SEM adopted because abstract and Table 1 differ.
DHA alone
Model: CT26 xenografts; female BALB/c nude mice; n=6/group
Route: Abdominal injection
Frequency: Days 7, 9 and 11
Treatment course: 3 injections; Day 15 tumor collection
Reported limits: No exact mean/SEM adopted because abstract and Table 1 differ.
RT alone
Model: CT26 xenografts; female BALB/c nude mice; n=6/group
Route: Tumor-directed irradiation
Frequency: Days 7, 9 and 11
Treatment course: 3 fractions; Day 15 tumor collection
Reported limits: No exact mean/SEM adopted because abstract and Table 1 differ.
DHA plus RT
Model: CT26 xenografts; female BALB/c nude mice; n=6/group
Route: Abdominal DHA injection; tumor-directed irradiation
Frequency: Days 7, 9 and 11; DHA 1 h before RT
Treatment course: 3 combined treatments; Day 15 tumor collection
Reported limits: No exact mean/SEM adopted because abstract and Table 1 differ.
Methods and source locations

Compound reported in the paper: Dihydroartemisinin; Compound label in the paper: DHA

Compound-level findings in the reported models. No validation of current A10310 lots or equivalence of suppliers; no clinical efficacy inference.

Methods 2.1–2.4; Results and Table 1; Figure 3; Discussion

Final tumor weight between treatment groups: Resected tumor weight on Day 15; Table 1 specifies mean ± SEM, n=6/group; no conflicting mean/SEM adopted — Table 1; Results; Figure 3

PBS control · Methods 2.1–2.4; Table 1; Figure 3

DHA alone · Methods 2.1–2.4; Table 1; Figure 3

RT alone · Methods 2.1–2.4; Table 1; Figure 3

DHA plus RT · Methods 2.1–2.4; Table 1; Figure 3

Specifications

Manufacturer Adooq Bioscience
CAS Number 71939-50-9
Formula C15H24O5
Molecular Weight 284.35
Synonyms dihydroqinghaosu; artenimol; DHA
SMILES
[H][C@@]1(C([H])([H])C2([H])[H])[C@]3([C@@]([C@@]4([H])C([H])([H])[H])([H])C([H])([H])C([H])([H])[C@@]1([H])C([H])([H])[H])OO[C@@]2(C([H])([H])[H])O[C@@]3([H])O[C@@]4([H])O[H]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 52 mg/mL (182.87 mM)
Water Insoluble
Ethanol Warmed: 10 mg/mL (35.16 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Dihydroartemisinin Research References

  1. [1] Zhou X, Zijlstra SN, Soto-Gamez A, et al. Artemisinin Derivatives Stimulate DR5-Specific TRAIL-Induced Apoptosis by Regulating Wildtype P53 Cancers (2020). PMID: 32899699 DOI: 10.3390/cancers12092514 Source material
  2. [2] Chen GQ, Benthani FA, Wu J, et al. Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis Cell death and differentiation (2020). PMID: 31114026 DOI: 10.1038/s41418-019-0352-3 Source material
  3. [3] Wang Y, Yang X, Xiao H, et al. Hypofractionated radiotherapy (RT) combined with dihydroartemisinin (DHA): No synergistic effect observed in a preliminary animal study Precision radiation oncology (2025). PMID: 41163978 DOI: 10.1002/pro6.70002 Source material

Publications

1 publication citing this product

  1. Xinyu Zhou, .et al. , Cancers (Basel), 2020, Sep; 12(9): 2514 PMID: 32899699

Added to your cart

View Cart Checkout
Loading...